Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis showdown: which method cleans blood better in the ICU?

NCT ID NCT06369064

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of continuous dialysis used in the ICU for patients with sudden kidney failure. One method uses a citrate-based blood thinner, the other uses heparin. The goal is to see if the citrate method is just as effective at removing waste from the blood. 80 adult ICU patients will be randomly assigned to one of the two methods, and their blood will be tested after 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dialysis procedure (CVVHD with citrate anticoagulation vs. CVVHDF with heparin anticoagulation)
What this could lead to
If successful, this could show that a simpler, citrate-based dialysis method works just as well as the standard heparin-based method, potentially simplifying care for ICU patients with kidney failure.
What could go wrong
This is a small, early-stage study (80 patients) at a single hospital, so results may not apply to all patients. The study compares two established techniques, so no breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Adult patients hospitalized in ICU * Undergo RRT session because of AKI stage 3 * At least one among criteria: pH \< 7,20 / Blood urea \> 30mM / Fluid overload uncontrolled by with PaCO₂ \< 35 mmHg or mixed acidosis with PaCO₂ \< 50 mmHg. * Oliguria lasting 72 hours or longer * Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization * Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation * Patient affiliated with Social Security. Exclusion criteria: * End-stage chronic kidney disease on dialysis * Intoxication with a dialyzable toxin (lithium * Criteria for emergency dialysis initiation: hyperkaliemia \>6,5mM with electrocardiographic signs * Medical contraindication to regional citrate: severe liver failure * Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding * Pregnant women, parturient or breast-feeding patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Continuous renal replacement therapy Intensive care unit

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nimes

    RECRUITING

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.